| abstract |
Provided is a pharmaceutical complex formulation for preventing or treating cardiovascular diseases, comprising (1) a first particle comprising an HMG-CoA reductase inhibitor and a basic additive; and (2) comprising aspirin a core and a second particle of an enteric coating layer coated on the core, wherein the first and second particles have a difference in average diameter of from 100 micrometers to 800 micrometers; a preparation method thereof; and verifying the quality thereof One way. The pharmaceutical complex formulation of the present invention can improve the stability of an active ingredient and avoid adverse effects between the active ingredients, thereby facilitating accurate quality verification of the pharmaceutical compound formulation. |